Australian Nasal Spray Shows Promise in Reducing Coronavirus by 96% in Animal Study

Preliminary results of a clinical study indicate that "the spray reduced the presence of coronavirus by up to 96% in ferrets" that had been exposed to SARS-CoV-2. At the helm is the Australian biotech company Ena Respiratory, which has developed a synthetic molecule called "INNA-051". This drug was designed to strengthen the immune system against the flu and winter colds, but has proven effective in the treatment of Covid-19.

"The INNA-051 compound acts by stimulating the innate immune system, the first line of defense against the invasion of pathogens in the body. By stimulating the immune response in this way with INNA-051 before infection, the ability of the COVID-19 virus to infect animals and replicate has been significantly reduced, the PHE study has shown. The study provides evidence that INNA-051 can be used as a standalone preventive antiviral therapy, complementary to vaccination programs. [...]," explain the researchers.

At a time when laboratories are working hard to develop a Covid vaccine, this drug can be used to cure coronavirus or even prevent infection. Patients "are really likely to eliminate it quickly with our treatment, or at least have only moderate symptoms of the Covid-19 disease," assures Christophe Demaison, CEO and founder of Ena Respiratory.